Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland
Research output: Contribution to journal › Journal article › Research › peer-review
Limited therapeutic options have highlighted the demand for new treatment modalities for patients with advanced neuroendocrine tumors (NET). Promising results of initial studies have warranted the implementation of peptide receptor radionuclide therapy (PRRT) in clinical practice. However, this treatment option still needs clinical evaluation.
Original language | English |
---|---|
Journal | Neuroendocrinology |
Volume | 93 |
Issue number | 3 |
Pages (from-to) | 189-96 |
Number of pages | 8 |
ISSN | 0028-3835 |
DOIs | |
Publication status | Published - 2011 |
ID: 40171591